IKBKB and neoplasm: Our current data complement these studies and demonstrate that inhibition of IKKβ in the tumour microenvironment inhibited osteoclast activity, enhanced osteoblast differentiation and reduced bone loss associated with osteolytic breast cancer metastasis.